Ahmet Doǧan

38.0k total citations · 3 hit papers
382 papers, 16.9k citations indexed

About

Ahmet Doǧan is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ahmet Doǧan has authored 382 papers receiving a total of 16.9k indexed citations (citations by other indexed papers that have themselves been cited), including 207 papers in Pathology and Forensic Medicine, 124 papers in Oncology and 117 papers in Molecular Biology. Recurrent topics in Ahmet Doǧan's work include Lymphoma Diagnosis and Treatment (192 papers), Chronic Lymphocytic Leukemia Research (72 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (66 papers). Ahmet Doǧan is often cited by papers focused on Lymphoma Diagnosis and Treatment (192 papers), Chronic Lymphocytic Leukemia Research (72 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (66 papers). Ahmet Doǧan collaborates with scholars based in United States, United Kingdom and Germany. Ahmet Doǧan's co-authors include Peter G. Isaacson, Jo Spencer, Jason D. Theis, Ming‐Qing Du, Julie A. Vrana, Karen L. Grogg, Ayoma D. Attygalle, Paul J. Kurtin, Jeffrey D. Gamez and Julie A. Vrana and has published in prestigious journals such as Nature, The Lancet and Nature Communications.

In The Last Decade

Ahmet Doǧan

368 papers receiving 16.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Immunohistochemical Study

1989 1.5k citations Ahmet Doǧan et al. profile →
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

2004 932 citations Ahmet Doǧan et al. profile →
Classification of amyloidosis by laser microdissection and mass spectrometry–based proteomic analysis in clinical biopsy specimens

2009 603 citations Jason D. Theis, Ahmet Doǧan et al. Blood profile →

Peers

Countries citing papers authored by Ahmet Doǧan

Since Specialization

Citations

This map shows the geographic impact of Ahmet Doǧan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmet Doǧan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmet Doǧan more than expected).

Fields of papers citing papers by Ahmet Doǧan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmet Doǧan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmet Doǧan. The network helps show where Ahmet Doǧan may publish in the future.

Co-authorship network of co-authors of Ahmet Doǧan

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmet Doǧan. A scholar is included among the top collaborators of Ahmet Doǧan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmet Doǧan. Ahmet Doǧan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants 2025 ·Blood Advances ·Paola Ghione, Diana Mandelker, Maria E. Arcila, Venkatraman Seshan, (unknown), Joseph Vijai, (unknown), Chad Vanderbilt, Joyce C. Pressley, Alexander Chan, Natasha Galasso, Ahmet Doǧan, Gilles Salles, Daphne de Jong, Flora E. van Leeuwen, Sarah McCue Horwitz	0
2	Tracking the FDA precision oncology drug approval landscape in OncoKB. 2024 ·Journal of Clinical Oncology ·Sarah P. Suehnholz, Ritika Kundra, Hongxin Zhang, Moriah H. Nissan, (unknown), (unknown), Nicole Fernandez, Subhiksha Nandakumar, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Aijazuddin Syed, A. Rose Brannon, Ross L. Levine, Ahmet Doǧan, Alexander Drilon, David B. Solit, Nikolaus Schultz, Debyani Chakravarty	1
3	SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma 2024 ·The Journal of Experimental Medicine ·(unknown), Shenqiu Wang, S. Parsa, Man Jiang, Alexander N. Gorelick, (unknown), (unknown), Elisa de Stanchina, Marjan Berishaj, Chunying Zhao, James A. Heward, (unknown), Omid Tavana, Jiayu Wen, Jude Fitzgibbon, Ahmet Doǧan, Anas Younes, Ari Melnick, Hans-Guido Wendel	5
4	Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma 2024 ·Clinical Cancer Research ·Maryam Pourmaleki, (unknown), (unknown), (unknown), Priyadarshini Kumar, Miguel Foronda, (unknown), Carl Campos, Mikhail Roshal, Nikolaus Schultz, Sohrab P. Shah, Andrea Schietinger, Nicholas D. Socci, Travis J. Hollmann, Ahmet Doǧan, Ingo K. Mellinghoff	7
5	A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas 2024 ·Blood ·Laurence de Leval, Philippe Gaulard, Ahmet Doǧan	10
6	CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas 2024 ·PubMed ·Paola Ghione, (unknown), Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul A. Hamlin, Anita Kumar, Matthew J. Matasar, Colette Owens, Alison J. Moskowitz, Lorenzo Falchi, David J. Straus, Steven M. Horwitz, Gilles Salles, Ahmet Doǧan, Andrew D. Zelenetz	1
7	Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop 2023 ·American Journal of Clinical Pathology ·Amy S. Duffield, Ahmet Doǧan, Catalina Amador, James R. Cook, Magdalena Czader, John R. Goodlad, Reza Nejati, Wenbin Xiao, Lanie E. Happ, (unknown), (unknown), (unknown), Sandeep S. Davé, (unknown), German Ott	3
8	Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia 2023 ·Science Advances ·Troy M. Robinson, Robert L. Bowman, (unknown), Ying Liu, (unknown), Qi Gao, (unknown), (unknown), Linde A. Miles, Sheng F. Cai, Adam Sciambi, (unknown), Christopher Famulare, Aaron D. Goldberg, Ahmet Doǧan, Mikhail Roshal, Ross L. Levine, Wenbin Xiao	24
9	Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations 2022 ·Blood Advances ·Kylee Maclachlan, Tina Bagratuni, Efstathios Kastritis, Bachisio Ziccheddu, Sydney X. Lu, Venkata Yellapantula, (unknown), Kimon V. Argyropoulos, Andriy Derkach, Elli Papaemmanuil, Ahmet Doǧan, Alexander M. Lesokhin, Saad Z. Usmani, Ola Landgren, Lia Palomba, Francesco Maura, Meletios Α. Dimopoulos	1
10	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma 2021 ·Modern Pathology ·(unknown), Ali Sakhdari, Huan Mo, Do H. Kim, Rashmi Kanagal‐Shamanna, Shaoying Li, Ken H. Young, Dennis P. O’Malley, Ahmet Doǧan, Preetesh Jain, Michael Wang, Timothy J. McDonnell, Roberto N. Miranda, Francisco Vega, L. Jeffrey Medeiros, Chi Young Ok	8
11	Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma 2020 ·Blood Cancer Journal ·Venkata D. Yellapantula, Malin Hultcrantz, Even H. Rustad, (unknown), (unknown), (unknown), (unknown), Heather Landau, (unknown), Sham Mailankody, Minal Patel, Juan S. Medina-Martínez, Juan Arango Ossa, Max F. Levine, Niccolò Bolli, Francesco Maura, Ahmet Doǧan, Elli Papaemmanuil, Yanming Zhang, Ola Landgren	1
12	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1 2020 ·JCO Precision Oncology ·Michael D. Kinnaman, (unknown), Mariko Yabe, Jonathan Powell, Jamal Benhamida, Martin Hasselblatt, Martín Neumann, Christian Vokuhl, Christian Koelsche, Andreas von Deimling, E. Anders Kolb, David B. Solit, Marc Ladanyi, Ahmet Doǧan, Neerav Shukla	1
13	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma 2019 ·Blood Cancer Journal ·Venkata D. Yellapantula, Malin Hultcrantz, Even H. Rustad, (unknown), (unknown), (unknown), (unknown), Heather Landau, (unknown), Sham Mailankody, Minal Patel, Juan S. Medina-Martínez, Juan Arango Ossa, Max F. Levine, Niccolò Bolli, Francesco Maura, Ahmet Doǧan, Elli Papaemmanuil, Yanming Zhang, Ola Landgren	35
14	Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma 2017 ·Blood ·Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander M. Lesokhin, Ahmet Doǧan, Aaron P. Rapoport, Mehmet H. Kocoglu, (unknown), Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva, Zeba N. Singh	146
15	Next Generation Sequencing (NGS) Based IGH and TCR Clonality Assays Provide Excellent Specificity and Sensitivity for Routine Clonal Characterization and Monitoring of Lymphoproliferative Disorders 2017 ·Blood ·Maria E. Arcila, Mustafa Syed, Wayne Yu, (unknown), (unknown), Caleb Ho, Kseniya Petrova‐Drus, Mikhail Roshal, Jae H. Park, Ola Landgren, Ahmet Doǧan, Khédoudja Nafa	2
16	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry 2016 ·Blood ·Taxiarchis Kourelis, Surendra Dasari, Jason D. Theis, Marina Ramı́rez-Alvarado, Paul J. Kurtin, Morie A. Gertz, Steven R. Zeldenrust, Roman M. Zenka, Ahmet Doǧan, Angela Dispenzieri	106
17	Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Jennifer L. Kelly, Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan, Alice H. Wang, Thomas E. Witzig, Timothy G. Call, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	34
18	Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing 2010 ·Blood ·Andrew L. Feldman, Ahmet Doǧan, Jeremy C. Smith, Mark E. Law, Stephen M. Ansell, Sarah H. Johnson, Julie C. Porcher, Nazan Özsan, Eric D. Wieben, Bruce W. Eckloff, George Vasmatzis	197
19	Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course 2008 ·Journal of Clinical Oncology ·(unknown), Brian Patrick O’Neill, Mark E. Law, Paul A. Decker, David M. Kurtz, Caterina Giannini, Alyx B. Porter, Paul J. Kurtin, Patrick B. Johnston, Ahmet Doǧan, Ellen D. Remstein	78
20	MALT lymphoma with t(11;18)(q21;q21) fails to respond to H-pylori eradication therapy 2001 ·UCL Discovery (University College London) ·(unknown), A. Ruskoné-Fourmestraux, Anne Lavergne‐Slove, (unknown), Thierry Jo Molina, Yoram Bouhnik, (unknown), (unknown), Ahmet Doǧan, Françis Mégraud, Rambaud Jc, MQ Du, PG Isaacson	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact